Guru Ownership Trend
Guru Analysis for Rhythm Pharmaceuticals, Inc. (RYTM)
Rhythm Pharmaceuticals, Inc. (RYTM), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q3 2026, a total of 7 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $163.87 M.
Top institutional holders include Steven Cohen and Stanley Druckenmiller.
Institutional sentiment is currently Strongly Bullish. This is evidenced by a $56.41 M net inflow during the quarter.
Recent activity highlights Ken Fisher who opened a new position. Conversely, Joel Greenblatt reduced exposure by 7.4%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q3 2026)
Guru Consensus (Q3 2026)
FAQs for Rhythm Pharmaceuticals, Inc. (RYTM)
Major holders include Steven Cohen ($69.17 M), Stanley Druckenmiller ($25.7 M), Ken Fisher ($10.09 M). According to the latest reported data, 7 tracked investment managers collectively hold approximately 1.36 M shares.
According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $56.41 M, with 6 managers increasing positions and 2 managers reducing holdings.
During the most recent reporting period, 1 managers trimmed their positions, while 1 fully exited RYTM. The total reported sell value was $1.58 M.
Yes, 2 managers opened new positions in RYTM, and 4 increased their existing holdings. The total reported buy value was $57.99 M.